Ecinq 30 mg (Ulipristal Acetate): Clinical Pharmacist Monograph on Emergency Contraception, Mechanism, 120-Hour Window, and Drug Interactions

Figure 1: Ecinq 30 mg oral tablet – Secondary packaging and presentation for emergency contraception.

1. What is Ecinq (Ulipristal Acetate)?

In clinical reproductive healthcare and outpatient pharmacotherapy, **Ecinq 30 mg** represents a second-generation emergency contraceptive pill (ECP). Unlike traditional first-generation emergency contraceptives that rely on the synthetic progestin levonorgestrel (such as Plan B One-Step, Postinor, or NorLevo), Ecinq utilizes **ulipristal acetate**, an advanced non-steroidal selective progesterone receptor modulator (SPRM).

The drug is formulated specifically as an urgent post-coital intervention for women who have engaged in unprotected penile-vaginal intercourse, experienced a mechanical barrier failure (such as condom rupture, slippage, or incorrect placement), missed consecutive doses of combined oral contraceptive pills (COCPs), experienced progestin-only pill (POP) timing delays, or suffered sexual assault.

A vital pharmacological distinction must be emphasized from the outset: **Ecinq is exclusively an anovulatory and anti-ovulatory emergency contraceptive; it is not an abortifacient.** It shares structural homologies with the antiprogestin mifepristone (RU-486), but the 30 mg dose of ulipristal acetate used in Ecinq does not possess the capacity to terminate an established, implanted pregnancy, nor does it disrupt post-implantation embryogenesis. If a woman is already pregnant at the time of ingestion, Ecinq will not disrupt the gestational sac, will not induce uterine evacuation, and will not increase the risk of fetal teratogenicity. Its clinical utility lies entirely in the prevention of fertilization by manipulating the neuroendocrine timing of ovulation.

Figure 2: Ulipristal acetate 30 mg oral tablet – A selective progesterone receptor modulator engineered for post-coital emergency intervention.

2. Ingredients & Mechanism of Action

The pharmacodynamic superiority of Ecinq over historical emergency contraceptive options stems from its receptor-binding profile. Ulipristal acetate acts as an orally active synthetic selective progesterone receptor modulator characterized by tissue-specific, mixed agonistic and antagonistic effects on human progesterone receptors (PR-A and PR-B).

The Biological Race: Ovulatory Arrest and Follicular Physiology

Human spermatozoa possess the physiological capacity to maintain viability, motility, and fertilizing competence inside the crypts of the female cervix and upper genital tract for up to **120 hours (5 days)** following coitus. If ovulation occurs at any point during this 5-day lifespan, fertilization within the ampulla of the fallopian tube is probable.

The primary mode of action of Ecinq 30 mg is **follicular rupture delay**. In clinical pharmacodynamic trials, administration of ulipristal acetate suppresses the growth of the lead dominant ovarian follicle, postponing rupture for at least **5 to 6 days**. By delaying follicular rupture, the viable lifespan of the spermatozoa residing within the reproductive tract expires naturally before an oocyte is released.

Why Ulipristal Outperforms Levonorgestrel: The LH Surge Paradigm

The key clinical difference between ulipristal acetate and levonorgestrel centers on their behavior relative to the **luteinizing hormone (LH) surge**:

• Levonorgestrel’s Limitation: Levonorgestrel is capable of inhibiting ovulation *only* if administered prior to the beginning of the initial LH rise. Once serum LH concentrations begin their upward trajectory toward the ovulatory peak, levonorgestrel exhibits an ovulation-inhibition failure rate of almost 100%, rendering it ineffective on the days of highest conception probability (cycle days -2 to 0 relative to ovulation).
• Ulipristal’s Molecular Dominance: Ulipristal acetate exerts direct antagonistic actions within both the anterior pituitary gland and follicular granulosal cells. It successfully delays follicular rupture even when administered **after the LH surge has already begun** (up until the immediate LH peak). Clinical trials confirm that when dominant follicles reach a diameter ≥ 18 mm—where levonorgestrel fails—ulipristal acetate prevents follicular collapse in up to 78% of cases, providing protection late into the fertile window.

3. Clinical Indications & Critical Therapeutic Window

Ecinq 30 mg is indicated for emergency post-coital contraception in women of reproductive age following:

• Unprotected penile-vaginal intercourse without baseline contraception.
• Known or suspected primary barrier failure (condom slippage, breakage, puncture, or early removal).
• Significant oral contraceptive adherence errors:
  • Missing two or more consecutive combined oral contraceptive pills (COCPs) containing ethinyl estradiol during the first week of a cycle, accompanied by unprotected intercourse during the prior 5 days.
  • A delay of >3 hours in taking a traditional progestin-only pill (POP), or a delay of >12 hours for desogestrel-containing POPs, followed by intercourse.
• Late administration of long-acting depot medroxyprogesterone acetate (DMPA) injections (exceeding 13 to 15 weeks from the previous dose).
• Accidental dislodgement, expulsion, or delayed replacement of a transdermal contraceptive patch or combined contraceptive vaginal ring.
• Cases of non-consensual sexual contact (sexual assault) where baseline contraceptive coverage is absent or uncertain.

Figure 3: Time-to-treatment relationship – While Ecinq is active up to 120 hours, earlier administration provides superior pregnancy risk reduction.

The 120-Hour Window: Efficacy Dynamics Over Time

While levonorgestrel demonstrates a marked decline in efficacy after 72 hours—and carries no regulatory indication between 72 and 120 hours—pooled clinical trials published in The Lancet demonstrate that **ulipristal acetate maintains consistent pregnancy prevention throughout the entire 120-hour (5-day) timeframe**.

Across randomized controlled trials, ulipristal acetate reduced the risk of unintended pregnancy by **almost 60% compared to levonorgestrel**, preventing up to 85% of expected pregnancies when taken within 120 hours. However, because ovulation can occur at any moment during the menstrual cycle, clinical guidelines emphasize that **Ecinq should be ingested as rapidly as possible** following coitus. If follicular rupture occurs prior to tablet ingestion, post-coital pharmacotherapy will fail.

4. Dosage Regimens & Administration Protocols

Administration of Ecinq 30 mg follows a standardized, single-dose oral protocol designed to minimize complexity during acute patient distress:

Figure 4: Standard administration: Take one whole 30 mg tablet orally with water as soon as possible within 120 hours.

• Standard Regimen: Ingest one single 30 mg tablet orally with a glass of water at any time during the menstrual cycle.
• Food Intake: Ecinq may be taken with or without food. Although high-fat meals slightly delay the time to peak concentration (T_max shifts from 0.75 hours to 3 hours), total systemic exposure (AUC) remains biologically equivalent, meaning dietary status does not impact clinical efficacy.
• Repeated Coitus in the Same Cycle: If additional episodes of unprotected intercourse take place *after* taking Ecinq, the initial dose does not confer ongoing protection. However, repeating ulipristal acetate within the same cycle is generally not advised due to potential endocrine disruption; barrier protection (condoms) must be used until the next menses.

The 3-Hour Emesis Protocol

A critical clinical parameter is gastrointestinal absorption time:

• Vomiting Within 3 Hours of Ingestion: The active pharmaceutical ingredient may have been expelled prior to adequate mucosal absorption. **A replacement 30 mg tablet must be ingested immediately.** If persistent nausea is present, an oral antiemetic (such as metoclopramide 10 mg or ondansetron 4–8 mg) may be administered 30 minutes before taking the repeat dose.
• Vomiting Occurring After 3 Hours: Complete gastrointestinal absorption into the systemic circulation has occurred. No replacement tablet or dosage adjustment is required.

5. Adverse Drug Reactions & Contraindications

Ulipristal acetate 30 mg is generally well tolerated. Adverse effects are characteristically self-limiting, mild-to-moderate in intensity, and resolve spontaneously within 24 to 48 hours.

Figure 5: Anticipated post-administration symptoms: transient headache, nausea, pelvic cramping, and minor menstrual timing shifts.

Reported Adverse Reactions by Frequency

• Common (≥10% incidence): Headache (18%), nausea (12%), abdominal discomfort or lower pelvic cramping (12%), dysmenorrhea (9%).
• Less Common (1% to 10% incidence): Dizziness, generalized fatigue, breast tenderness (mastalgia), mood swings, back pain, transient hot flashes.
• Menstrual Timing Shifts: Because Ecinq suppresses follicular maturation, menstrual timing alterations are expected:
  • Approximately 75% of women menstruate within ±7 days of their expected date.
  • Menses arrives earlier than expected in ~7% of patients.
  • Menses is delayed by more than 7 days in ~18% of patients.
  • Intermenstrual spotting occurs in roughly 9% of cycles post-treatment.

Contraindications

• Absolute Contraindications: Known hypersensitivity or anaphylaxis to ulipristal acetate or any excipients; known or diagnosed ongoing intrauterine or extrauterine pregnancy (ineffective and clinically non-indicated).
• Severe Hepatic Impairment: Because ulipristal is extensively cleared via hepatic CYP3A4-mediated oxidation, it is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C).
• Severe Asthma Unresponsive to Oral Steroids: Ulipristal acetate exhibits anti-glucocorticoid activity; caution is warranted in severe persistent asthma managed with systemic glucocorticoids.
• Rare Hereditary Metabolic Conditions: Contains lactose monohydrate; contraindicated in individuals with rare galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption.

6. Critical Drug & Hormonal Interactions

Ulipristal acetate exhibits critical pharmacokinetic and pharmacodynamic interactions that require strict adherence to clinical management guidelines:

1. The Progestin Contraceptive Conflict: The Mandatory 5-Day Waiting Window

A frequent clinical prescribing error occurs when regular hormonal contraception (pills, patches, rings, or injections) is restarted immediately after taking Ecinq.

• The Receptor Competition Mechanism: Ulipristal acetate and synthetic progestins (e.g., levonorgestrel, desogestrel, drospirenone, medroxyprogesterone) bind competitively to the same progesterone receptors. If a woman immediately takes a progestin-containing birth control pill right after Ecinq, the exogenous progestin can displace ulipristal from the receptors, reversing its ability to prevent ovulation. Concurrently, ulipristal can impair the contraceptive efficacy of the daily birth control. Both medications can fail.
• The Clinical Rule: Guidelines from the Faculty of Sexual and Reproductive Healthcare (FSRH) and the US Centers for Disease Control and Prevention (CDC) state that **patients must wait at least 5 days (120 hours) after taking ulipristal acetate before initiating or resuming any progestin-containing hormonal contraceptive**.
• Barrier Method Coverage: During the 5-day post-Ecinq waiting period *and* for the subsequent **7 days of continuous pill taking** (14 days for the Qlaira pill; 2 days for traditional POPs), patients must use a barrier method (male condoms) or abstain from coitus.

2. Hepatic Cytochrome P450 (CYP3A4) Modulators

Ulipristal is metabolized primarily via the CYP3A4 isoenzyme system:

• Potent CYP3A4 Inducers: Co-administration with potent enzyme inducers—including rifampin, carbamazepine, phenytoin, phenobarbital, primidone, efavirenz, and the herbal extract St. John’s Wort (Hypericum perforatum)—dramatically accelerates ulipristal metabolism, reducing plasma AUC by 50% or more and risking contraceptive failure.
  Clinical Management: In women who have used a liver enzyme-inducing drug within the preceding 28 days, emergency oral ulipristal is not recommended. The **copper intrauterine device (Cu-IUD)** is the absolute first-line recommendation. If the Cu-IUD is refused or clinically unfeasible, a double dose of levonorgestrel (3 mg total) is indicated, as doubling ulipristal dosage is unvalidated.
• Gastric pH Altering Agents: Histamine H2 receptor antagonists (e.g., famotidine) and proton pump inhibitors (e.g., omeprazole, pantoprazole) increase intragastric pH, leading to a modest reduction in ulipristal C_max. However, overall bioavailability remains sufficient, and no dosage adjustments are clinically warranted.

7. Special Populations & Clinical Considerations

Clinical decisions surrounding emergency contraception must account for individual patient physiology:

The Impact of High Body Mass Index (BMI) and Obesity

Extensive epidemiological studies indicate that the clinical efficacy of oral emergency contraceptives is reduced in women with elevated body weight:

• Levonorgestrel Threshold: Levonorgestrel’s pregnancy-prevention efficacy begins to decline in women weighing over 70 kg (154 lbs) or with a BMI > 25 kg/m², dropping to near-placebo levels in women with a BMI ≥ 30 kg/m².
• Ulipristal Acetate Durability: Ulipristal acetate (Ecinq) maintains significantly greater contraceptive efficacy at higher weight classes. Its pregnancy prevention rate remains clinically effective up to a **BMI of 30 to 35 kg/m² (or body weight up to 85–90 kg)**.
• Severe Obesity (BMI > 35 kg/m²): In individuals with a BMI > 35 kg/m², both oral options experience efficacy declines. While Ecinq remains the superior oral option over levonorgestrel, clinicians must inform patients that the **copper intrauterine device (Cu-IUD) or levonorgestrel 52 mg IUD** provides the highest efficacy regardless of body weight.

Lactation & Breastfeeding Guidelines

Ulipristal acetate is a lipophilic compound that distributes into human breast milk. A nursing infant can ingest an estimated 0.75% of the maternal dose:

• The 7-Day Express-and-Discard Protocol: Manufacturer labeling and international health guidelines advise that **breastfeeding should be paused for 7 days (one week)** following the ingestion of Ecinq 30 mg.
• During this 7-day interval, the mother should use a breast pump to express and discard breast milk to maintain milk supply and prevent mastitis.
• Alternative: If pausing breastfeeding for 7 days is unfeasible or disruptive, **levonorgestrel 1.5 mg** serves as an alternative oral option, as breastfeeding can safely resume 8 hours following levonorgestrel administration.

8. Therapeutic Alternatives Comparison

Selecting the appropriate post-coital emergency method requires comparing clinical timing, efficacy, access, and long-term contraceptive needs:

9. Regional Availability & Authentication Guide

Regulatory classification for ulipristal acetate varies significantly across geographical markets:

• United Kingdom & European Union: Marketed primarily as *ellaOne*, it holds non-prescription status (Pharmacy Medicine / OTC), allowing direct dispensing by community pharmacists without a physician’s prescription following an in-pharmacy consultation.
• United States: Marketed as *ella*, it remains classified as a Prescription-Only Medication (Rx), requiring an authorized prescription from a physician, nurse practitioner, or certified clinical pharmacist.
• Middle East & GCC (Saudi Arabia, UAE, Egypt, Kuwait): Ecinq and regional equivalents are typically stocked in community and hospital pharmacies under Prescription-Only or Behind-the-Counter regulations. Patients should confirm availability promptly, as emergency contraception supplies can vary across regional pharmacy inventories.

Figure 6: Professional clinical consultation ensures authentic pharmaceutical sourcing and proper post-treatment follow-up.

Preventing Counterfeits and Verifying Authenticity

Because post-coital contraceptives carry emotional urgency, an illicit secondary grey market exists online. To ensure medication safety:

• Always source Ecinq from licensed, brick-and-mortar pharmacies or accredited healthcare delivery services. Avoid purchasing from unregulated social media vendors or unlicensed e-commerce websites.
• Verify that the external carton features a clear batch lot number, manufacturing date, and tamper-evident seal.
• Check the internal blister package for intact aluminum foil; the tablet is typically a round, biconvex, curved white-to-marble-white tablet debossed with standard manufacturer identification codes.

Storage Parameters

• Store at controlled room temperature between 15°C and 30°C (59°F to 86°F).
• Keep the blister inside the original cardboard carton to protect the photo-sensitive active ingredient from prolonged direct ultraviolet light exposure. Keep away from excessive humidity (do not store in steamy bathrooms).

10. Clinical Pharmacist Verdict & Bottom Line

The Bottom Line: Ecinq 30 mg (ulipristal acetate) represents the first-line oral standard of care for emergency post-coital contraception. For women presenting between 0 and 120 hours after unprotected intercourse—particularly those presenting beyond 72 hours or with a BMI over 25 kg/m²—Ecinq is clinically superior to levonorgestrel. However, its effectiveness depends on immediate administration before ovulation, strict adherence to the 5-day waiting period before resuming regular hormonal contraceptives, and appropriate follow-up if menstrual bleeding is delayed.

❓ Frequently Asked Clinical Questions